This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Biohaven’s Nurtec ODT in treating migraines

Ticker(s): BHVN

Who's the expert?

Institution: Dartmouth-Hitchcock Medical Center

  • Clinical Neurologist. Director of the Dartmouth Headache Center, and Professor of Neurology at Geisel School of Medicine, Dartmouth.
  • Treats~150 migraine patients per month. 
  • Previously investigator in the rimegepant Phase 2 trial when it was owned by BMS. and has published over 330 peer-reviewed manuscripts, editorials, and books.

Interview Questions

Please tell us about your clinical experience. How many patients with migraines do you see on a yearly basis? What is the standard of care, and how is Nurtec ODT fitting in this space?

Added By: joe_mccann

How many patients achieve good outcomes with standard of care medication? What side-effects are associated with standard of care drugs?

Added By: joe_mccann

How often do people end up not getting good control of migraines and wanting to try out new medication? Is CGRP medication seen as a last-to-try option?

Added By: joe_mccann

Can you talk to us more about the potential of monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor and the impact it’s having on migraine management?

Added By: joe_mccann

Since 2018, the FDA has approved 6 drugs that block either CGRP or its receptor. Can you tell us which are the most successful in your practice, and the reasons why?

Added By: joe_mccann

In large, it’s been reported that CGRP-targeted drugs are similarly effective. In those who take them to prevent migraine, they almost entirely cease attacks for about 25% of people and another 50% or so report moderate improvement, with fewer attacks, and the rest don’t respond at all. What differentiation have you seen between available drugs, in those aspects?

Added By: joe_mccann

Biohaven reports that its drug is the only one of the CGRP drugs to demonstrate efficacy in both the acute and preventive treatment of migraine. How important is this aspect in deciding what’s best for the patients?

Added By: joe_mccann

How valid are the concerns that because CGRP is a potent dilator of blood vessels, blocking it might raise the long-term risk of stroke or heart attack?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.